Corporate Overview

Zero Candida Technologies, Inc. (TSXV:ZCT), is bringing female healthcare into the 21st century, transforming the treatment of Vulvo-Vaginal Candidiasis (“VVC”), which affects approximately 75% of women worldwide. Up to 10% of cases are recurrent (4+ episodes per year) and increasingly drug-resistant, as current treatments fail to address the root cause effectively.

Without chemicals or side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized treatment. Their first of its kind technology is recognized by medical experts globally, effectively treating Candida fungus with a 99.999% success in preclinical tests. ZC has conducted successful safety trials on large animals and signed preclinical agreements with hospitals in Israel and Europe. The company is finalizing its product for a human clinical trial scheduled for June 2025.

Beyond treating VVC, ZC aims to revolutionize gynecological care with hybrid medical technologies, expanding access to underserved populations, including those in developing countries.